Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Search
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)
Hang Seng
17,626.29
(-0.05%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,676.34
(0.2%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,398.20
(0.15%)
Lithium
41.42
(1.37%)
Iron Ore
101.4
(-2.01%)

AdAlta (ASX: $1AD) advances AD-214 and i-CAR cell therapy partnering at key industry events

AdAlta reports positive progress on partnering initiatives at key January conferences


AdAlta Limited (ASX: $1AD) has made significant strides in advancing its AD-214 and i-CAR cell therapy partnering programs during the JPMorgan Healthcare Conference and Advanced Therapies Week. The company also announced the completion of the AD-214 Phase I extension study, with final results expected by the end of February 2024.

Executive commentary on partnering initiatives and progress


AdAlta's CEO and Managing Director, Tim Oldham, expressed satisfaction with the progress made in January towards AD-214 partnering goals and the positive reception of the i-CAR-T cell therapy strategy. He emphasized the considerable upside potential for shareholders if the partnering initiatives are successful, while refraining from making forecasts about their ultimate value.

Summary of AdAlta's partnering progress and outlook


AdAlta has actively engaged in partnering activities at key industry conferences, with a focus on securing financing for Phase II clinical studies of AD-214 and establishing new co-development collaborations for i-body-enabled i-CAR-T therapies. The completion of the AD-214 Phase I extension study marks a significant milestone, with final results expected to support partnering by the end of February 2024. The company's i-CAR-T strategy has received positive feedback, indicating the potential to develop a valuable clinical stage pipeline of assets beyond AD-214. AdAlta's ambitions to enable advanced cell and gene therapy products reflect its commitment to addressing challenging medical conditions and maximizing the potential of its i-body® technology platform.

Sourcehttps://announcements.asx.com.au/asxpdf/20240122/pdf/05zmc94vp8j16s.pdf

Share to Social
0 Comments
Inline Feedbacks
View all comments

Stock Piper AI Index Coming Soon!

Join our Newsletter to gain exclusive insight and be notified once we are live.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

Get all the latest market updates straight to your inbox.

By clicking Subscribe, you agree to our Terms & Conditions